F. Hoffmann-La Roche Ltd

What F. Hoffmann-La Roche Ltd does

F. Hoffmann-La Roche Ltd, founded in 1896 and headquartered in Basel, Switzerland, is a publicly traded global healthcare company (SIX Swiss Exchange: RX.SIX) that combines pharmaceutical and diagnostics divisions to deliver personalized medicine. The Pharmaceutical Division generated CHF 11.5 billion in Q1 2026 (+7% at constant exchange rates) across oncology (14 cancer medications treating over 1 million patients annually, including Phesgo, Hemlibra, Vabysmo, Kadcyla), immunology, ophthalmology, neuroscience (Ocrevus for multiple sclerosis; 14 medicines in development across 115 trials), and hematology. The Diagnostics Division generated CHF 3.3 billion in Q1 2026 (+3% at constant exchange rates) spanning in vitro diagnostics, tissue diagnostics, point-of-care testing, digital pathology with AI capabilities, and the cobas molecular diagnostic platform; the Accu-Chek brand covers diabetes care with glucose meters, insulin delivery, and digital management tools.

The company's business model is built on direct enterprise sales to hospitals, cancer treatment centers, and government health systems (e.g., a strategic collaboration with Jamaica's Ministry of Health and Wellness since 2015), supplemented by channel partners for diabetes care products. Revenue derives from pharmaceutical product sales (including companion diagnostics and licensing/royalties) and from diagnostic hardware, reagents, and digital health platforms such as Navify Sample Tracking (launched May 2023) and an AI-driven digital pathology platform developed with Ibex Medical Analytics and AWS (October 2023). Recent FDA approvals include Lunsumio VELO SC (December 2025) and the PATHWAY anti-HER2 label expansion (January 2025), while major recent M&A includes LumiraDx's point-of-care platform (USD 350M, July 2024), Carmot Therapeutics (obesity/diabetes pipeline), Poseida Therapeutics (gene therapy), and the announced SAGA Diagnostics deal (April 2026).

Roche operates in more than 100 countries through wholly-owned subsidiaries including Genentech, Ventana Medical Systems, and Roche Services & Solutions Americas (800+ collaborators in Costa Rica), and has committed USD 50 billion to U.S. diagnostics manufacturing and research, signaling a multi-year capacity and capability expansion rather than a near-term pivot.

Name

F. Hoffmann-La Roche Ltd

Legal name

F. Hoffmann-La Roche Ltd

Website

https://roche-ccav.com

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

F. Hoffmann-La Roche Ltd is a Basel-based global pharmaceutical and diagnostics company that develops personalized medicines across oncology, immunology, neuroscience, ophthalmology, and hematology, and supplies in vitro diagnostics, digital pathology, and Accu-Chek diabetes care products to healthcare providers and governments in 100+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals and In Vitro Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Biopharmaceutical products
• In vitro diagnostics
• Personalized oncology
• Diabetes care devices
• Digital pathology

Headquarters

HQ city

Klein-basel

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Roche's Pharmaceuticals Division generated CHF 11.5 billion in Q1 2026, growing +7% at constant exchange rates. Key products driving growth include Xolair (+26%), Phesgo (+27%), Hemlibra (+13%), Vabysmo (+13%), and Ocrevus (+6%), which collectively achieved CHF 5.3 billion in sales (+14% CER).
2. Diagnostic Products and Services: Roche's Diagnostics Division generated CHF 3.3 billion in Q1 2026, growing +3% at constant exchange rates. The division includes in vitro diagnostics, tissue diagnostics, point-of-care testing, and digital pathology solutions.
3. Companion Diagnostics: Roche committed USD 50 billion to U.S. diagnostics manufacturing and research, supporting companion diagnostics and personalized medicine approaches linked to targeted therapies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

F. Hoffmann-La Roche Ltd operates two integrated divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division develops and markets biologic and small-molecule therapies across oncology, immunology, neurosciences, ophthalmology, hematology, and respiratory diseases (key brands include Xolair, Phesgo, Hemlibra, Vabysmo, Ocrevus, Lunsumio, Kadcyla, and Ronapreve). The Diagnostics Division supplies in vitro diagnostic analyzers, reagents, and molecular tests (cobas platform), companion diagnostics linked to targeted therapies, AI-driven digital pathology tools, and the Navify cloud-based specimen tracking system, supported by the Accu-Chek diabetes-care device platform.

Product overview

F. Hoffmann-La Roche Ltd operates as an integrated healthcare company combining pharmaceutical and diagnostic divisions to deliver personalized medicine. The product portfolio spans multiple therapeutic areas: oncology (14 cancer medications treating over 1 million patients annually, including Kadcyla, Phesgo, and Ronapreve), immunology (autoimmune and respiratory disease treatments), neurosciences (MS treatments including Ocrevus, Alzheimer's, Parkinson's), ophthalmology (Vabysmo for retinal diseases), and diabetes care (Accu-Chek® platform for blood glucose monitoring and management). The Diagnostics division provides molecular diagnostics (cobas platform for HIV, infectious diseases), digital pathology with AI capabilities, and specimen tracking solutions (Navify Sample Tracking). Key growth products in 2026 include Xolair (+26%), Phesgo (+27%), Hemlibra (+13%), Vabysmo (+13%), and Ocrevus (+6%). The company also offers digital health platforms including AI-driven pathology tools and cloud-based workflow solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Accu-Chek Diabetes Care Platform Comprehensive diabetes care platform offering blood glucose meters, lancing devices, insulin delivery systems, and digital data management solutions for people with diabetes, distributed via pharmacies, medical supply distributors, and Accu-Chek customer service.
• Oncology Portfolio

Named customers2 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core, major and minor.

• C4 TherapeuticscoreStrategic or Co-development Partner · 1 April 2026Collaboration to develop degrader-antibody conjugates, combining C4 Therapeutics' degrader expertise with Roche's antibody-drug conjugate platform for novel cancer therapeutics.
• LumiraDxmajorTechnology or Integration · 1 July 2024Roche acquired LumiraDx's point-of-care technology platform to strengthen its diagnostic testing presence in primary care environments, expanding decentralized diagnostics capabilities using LumiraDx's multi-assay platform.
• Carmot TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Roche acquired Carmot Therapeutics gaining access to its R&D pipeline and Chemotype Evolution discovery platform focused on obesity and diabetes treatments.
• Ibex Medical AnalyticscoreTechnology or Integration · 1 October 2023Partnership with Ibex Medical Analytics and Amazon Web Services to deploy AI-driven digital pathology tools for breast and prostate cancer diagnosis, integrating AI-powered pathology image analysis into Roche's diagnostic workflow.
• Amazon Web ServicescoreTechnology or Integration · 1 October 2023Cloud infrastructure partnership for AI-driven digital pathology deployment, supporting scalable and secure pathology image analysis and storage capabilities.
• Healthcare InstitutionscoreTechnology or Integration · 1 May 2023Launch of Navify Sample Tracking, a cloud-based digital system designed to enhance specimen traceability and streamline diagnostic workflows across healthcare environments.
• Ministry of Health and Wellness of JamaicacoreStrategic or Co-development Partner · 1 January 2015Strategic collaboration since 2015 to strengthen access to accurate diagnoses and personalized treatments for cancer patients, with special focus on breast cancer. Includes implementation of immunohistochemistry equipment at National Public Health Hospital and establishment of national standardization protocols.
• SAGA DiagnosticscoreStrategic or Co-development PartnerRoche entered a definitive agreement to acquire SAGA Diagnostics, a company specializing in molecular diagnostics, to expand its oncology diagnostics capabilities.
• PfizerminorStrategic or Co-development PartnerPartnership between Roche Diagnostics and Pfizer for home-based diagnostic tests, enabling patient monitoring and diagnostics outside traditional healthcare settings.
• Union International against Cancer (UICC)majorStrategic or Co-development PartnerRoche is a strategic partner of UICC, sharing a common vision for more equitable, person-centered cancer care based on global collaboration with local impact. Partnership supports World Cancer Day initiatives.
• Poseida TherapeuticscoreStrategic or Co-development PartnerRoche's acquisition of Poseida Therapeutics strengthens its gene therapy pipeline and manufacturing capabilities for cell and gene therapy development.
• GeneDx, LLCminorStrategic or Co-development PartnerBoth F. Hoffmann-La Roche Ltd and GeneDx are pursuing strategic initiatives such as partnerships and acquisitions to expand their presence in the NICU Genetic Testing Market.
• Healthcare Regulatory Authorities (FDA)coreOthersRoche received FDA approval for Lunsumio VELO SC formulation in December 2025, and FDA label expansion for PATHWAY anti-HER2/neu Rabbit Monoclonal Primary Antibody in January 2025 for identifying eligible breast cancer patients.

Scale indicators8 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Danaher Corporation: Diversified life sciences and diagnostics company (Beckman Coulter, Cepheid, Leica Biosystems) competing with Roche in IVD analyzers, clinical chemistry, and molecular diagnostics; explicitly listed as a Roche CLIA competitor.
• Novartis AG: Swiss-headquartered global pharmaceutical company with comparable scale, therapeutic breadth (oncology, immunology, neuroscience), and a parallel diagnostics adjacency through its radioligand therapy platform. Closest geographic and strategic peer to Roche.
• AstraZeneca PLC: UK-headquartered global biopharma with overlapping oncology (Imfinzi, Tagrisso, Enhertu), respiratory, and cardiovascular franchises; also investing heavily in companion diagnostics and ADC platforms comparable to Roche.
• Sanofi S.A. French global biopharma competitor in immunology (Dupixent competes with Xolair in some indications), neurology, and rare diseases, with a parallel diabetes legacy and consumer health background.
• Abbott Laboratories: Direct peer in the diagnostics market, competing with Roche in CLIA immunoassay analyzers, point-of-care diagnostics, and molecular diagnostics; explicitly named alongside Siemens Healthineers, Danaher, and DiaSorin as Roche's CLIA competitors.
• AbbVie Inc. Global biopharmaceutical company with overlapping immunology (Humira/Skyrizi/Rinvoq) and oncology (Imbruvica, Venclexta) franchises; competes head-to-head with Roche's autoimmune and hematology portfolios.
• Merck & Co., Inc. Major U.S. pharmaceutical competitor directly overlapping with Roche in oncology (Keytruda competes with Roche's Tecentriq) and in immunology/vaccines, with similar blockbuster-revenue concentration.
• Pfizer Inc. Global pharmaceutical major that is both a Roche partner (home-based diagnostics collaboration) and a direct competitor across oncology, immunology, and infectious diseases with similar blockbuster-driven economics.
• Siemens Healthineers AG: Named Roche competitor in CLIA analyzers and a global diagnostics/in vitro diagnostics peer; also operates laboratory diagnostics services comparable to Roche's diagnostics division.
• Bristol-Myers Squibb Company: U.S. biopharma with directly overlapping immuno-oncology (Opdivo, Yervoy) and hematology franchises (Pomalyst, Empliciti) competing against Roche's Tecentriq, Hemlibra, and Lunsumio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/RocheCostaRica
• LinkedInlinkedin.com/company/roche-ccav

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about F. Hoffmann-La Roche Ltd